SPL Mapping FHIR R5 Implementation Guide, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 0.2.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-spl/ and changes regularly. See the Directory of published versions
Page standards status: Trial-use | Maturity Level: 1 |
{
"resourceType" : "ValueSet",
"id" : "valueset-genericFacilityMessageTypes",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet valueset-genericFacilityMessageTypes</b></p><a name=\"valueset-genericFacilityMessageTypes\"> </a><a name=\"hcvalueset-genericFacilityMessageTypes\"> </a><a name=\"valueset-genericFacilityMessageTypes-en-US\"> </a><ul><li>Include these codes as defined in <a href=\"http://loinc.org\"><code>http://loinc.org</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td><a href=\"https://loinc.org/71743-9/\">71743-9</a></td><td>GENERIC DRUG FACILITY IDENTIFICATION SUBMISSION</td></tr><tr><td><a href=\"https://loinc.org/72090-4/\">72090-4</a></td><td>IDENTIFICATION OF CBER-REGULATED GENERIC DRUG FACILITY</td></tr></table></li></ul></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "brr"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
"valueInteger" : 1,
"_valueInteger" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
"valueCanonical" : "http://hl7.org/fhir/us/spl/ImplementationGuide/hl7.fhir.us.spl"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
"valueCode" : "trial-use",
"_valueCode" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
"valueCanonical" : "http://hl7.org/fhir/us/spl/ImplementationGuide/hl7.fhir.us.spl"
}
]
}
}
],
"url" : "http://hl7.org/fhir/us/spl/ValueSet/valueset-genericFacilityMessageTypes",
"version" : "0.2.1",
"name" : "GenericFacilityMessageTypes",
"title" : "Generic Facility Message Types",
"status" : "active",
"experimental" : false,
"date" : "2024-12-10T07:56:13+00:00",
"publisher" : "HL7 International / Biomedical Research and Regulation",
"contact" : [
{
"name" : "HL7 International / Biomedical Research and Regulation",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/rcrim"
}
]
}
],
"description" : "The set of message types that are allowed as a Generic User Fee Facility submission.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "US",
"display" : "United States of America"
}
]
}
],
"copyright" : "This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc",
"compose" : {
"include" : [
{
"system" : "http://loinc.org",
"concept" : [
{
"code" : "71743-9",
"display" : "GENERIC DRUG FACILITY IDENTIFICATION SUBMISSION"
},
{
"code" : "72090-4",
"display" : "IDENTIFICATION OF CBER-REGULATED GENERIC DRUG FACILITY"
}
]
}
]
}
}